EADV 2025｜新突破，新期待

这次参加 EADV 在法国巴黎举办的这场盛会，我感受很多。这个会议的规模很大，同时，也有非常多我们中国的专家学者参加，也看到了很多生物制剂，包括（靶向）IL-23 的口服药物也在这个会议上有所展示。所以，还是有很多新的东西、新的治疗方法去给各个国家的科学家分享。非常高兴这次参加 EADV 的会议，也看到了生物制剂在很多炎症性皮肤病的领域里面有新的突破。我们中国未来的方向也是会针对这一块再做更深入、更广泛的研究。我觉得炎症性皮肤病，包括银屑病这些疾病，它未来的治疗方向还是跟生物制剂、靶向药物相关的药物可能更具有前景。  

I participated in this grand event held by EADV in Paris, France, and I felt a lot about it. The scale of this meeting is very large. At the same time, there are also many Chinese experts and scholars. I also saw many biologicals, including oral drugs targeting IL-23 were also presented at this conference. So, there are still many new treatment methods to be shared with scientists from various countries. It's a great pleasure to attend the EADV conference and I've also witnessed new breakthroughs in this field of inflammatory skin diseases. I think China's future direction will also be to do more in-depth and extensive research on this aspect. I think that for inflammatory skin diseases, including psoriasis, the future treatment direction may still be more promising with drugs related to biologicals and targeted drugs.